Navigation Links
ForteBio, Inc. Closes $25 Million In Series C Financing

Joseph D. Keegan, President and CEO, to Present at UBS Global Life Sciences


MENLO PARK, Calif., Sept. 23 /PRNewswire/ -- ForteBio(R), Inc., a leading supplier of label-free technology that accelerates the development of life science and pharmaceutical products, today announced the closing of $25 million in Series C financing, led by OrbiMed Advisors, a top global healthcare investment firm. MPM Capital also participated as a new investor in this financing round, as did existing investors Alloy Ventures, Latterell Venture Partners, The Vertical Group and Versant Ventures.

"With this new financing, ForteBio is well-positioned to continue to introduce industry-leading products and expand our market globally," said Joseph D. Keegan, Ph.D., President and Chief Executive Officer of ForteBio. "We are also delighted to add such renowned life science investors as OrbiMed Advisors and MPM Capital to our team and strongly value the continued support of our existing, highly-respected investors."

"ForteBio has successfully integrated its outstanding innovation capabilities in the U.S. and low-cost manufacturing capabilities in Asia to create superior products, enabling the life sciences industry worldwide," said Jonathan Wang, Ph.D., Managing Director for OrbiMed Asia. "OrbiMed is pleased to provide its strong resources in both the U.S. and Asia to support Dr. Keegan and his excellent management team to build ForteBio into a global leader." Dr. Wang, along with Kazumi Shiosaki, Ph.D., Managing Director of MPM Capital, will join the ForteBio board of directors.

Since launching its Octet(R) QK System in late 2005, ForteBio has grown rapidly. It now has 11 biosensors (consumables) on the market and counts all of the leading biotechnology companies and 18 of the top 20 pharmaceutical companies as customers, many of which have purchased multiple systems. This year ForteBio introduced its Octet RED system and additional biosensors, expanding its quantitation applications and broadening its small molecule kinetics capabilities. The company also added a European direct selling team and numerous distributors throughout the world this year in order to better serve its growing global pharmaceutical, biotechnology, academic and government customer base.

ForteBio also announced today that Dr. Keegan will present an update on company activities at the UBS Global Life Sciences Conference on Wednesday, September 24, 2008, at 2:30 p.m. EDT. His presentation will take place in Ballroom A at the Grand Hyatt Hotel in New York City. A live audio webcast of the presentation will be available at and will be accessible until October 25, 2008.

About OrbiMed Advisors, LLC

OrbiMed is the world's largest life sciences and healthcare-dedicated investment firm, with approximately $5 billion in assets under management. Since inception of its private equity investment activities in 1993, OrbiMed has successfully invested in close to 100 companies across a wide range of therapeutic categories and stages of development. OrbiMed's investment team includes approximately 30 experienced professionals with backgrounds in science, medicine, industry, finance and law. OrbiMed's professionals work together using a collaborative, team-oriented approach to support our portfolio companies, which has earned OrbiMed a reputation as a capital provider of choice for life sciences companies of all stages. OrbiMed has established the first pan-Asia life sciences-dedicated venture capital fund and has opened offices in Shanghai and Mumbai. For more information, visit

About ForteBio, Inc.

ForteBio is a venture capital-funded company providing analytical systems to accelerate life science and pharmaceutical development. These systems provide quantitation and kinetic information, enabling real-time analysis of biomolecular interactions. ForteBio's analytical capabilities allow significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with wholly owned subsidiaries in Shanghai and London. For more information, visit

CONTACT: Joseph D. Keegan, Ph.D., President and CEO

ForteBio, Inc.


SOURCE ForteBio, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
2. Genmab Discloses Target and Development Plans for HuMax-Inflam
3. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
4. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
5. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
6. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
7. BioVex Closes Second Round of Series E Financing
8. Pharmaxis Closes Share Purchase Plan
9. The closest look ever at native human tissue
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
Post Your Comments:
(Date:11/27/2015)... Kingdom , Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc ... company, announced today that it has closed the sale ... business to Guerbet (GBT- NYSE Euronext) in a transaction ... encompassed four manufacturing facilities and a total of approximately ... in the St. Louis area. ...
(Date:11/26/2015)... , November 26, 2015 ... --> Accutest Research Laboratories, a ... Research Organization (CRO), has formed a ... Center - Temple Health for joint ... ,     (Photo: ) , ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... a biotechnology company developing bioengineered organ implants for life-threatening ... will present at the LD Micro "Main Event" investor ... PT. The presentation will be webcast live and posted ... also be available at the conference for one-on-one meetings ...
Breaking Biology Technology:
(Date:11/19/2015)... NEW YORK , Nov. 19, 2015  Although ... the market is dominated by a few companies, according ... Qiagen. These companies own 51% of the market share of ... report, The World Market for Molecular Diagnostic ... "The market is still controlled by one ...
(Date:11/17/2015)... -- Paris from 17 th ... Paris from 17 th until 19 th ... has invented the first combined scanner in the world which ... surface. Until now two different scanners were required: one for ... on the same surface. This innovation is an ideal ...
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, ... in the development and sale of broadly enabling, pressure ... life sciences industry, today announced it has received gross ... $5 million Private Placement (the "Offering"), increasing the total ...  One or more additional closings are expected in the ...
Breaking Biology News(10 mins):